Compugen Ltd. (CGEN) Reports Q4 Revenue of $67.3 Million vs. $1.5 Million Last Year

Compugen Ltd. (NASDAQ:CGEN) is among the 11 Fastest Growing Penny Stocks to Buy Right Now.

Compugen Ltd. (CGEN) Reports Q4 Revenue of $67.3 Million vs. $1.5 Million Last Year

On March 2, 2026, Compugen Ltd. (NASDAQ:CGEN) reported fourth-quarter revenue of $67.3 million compared with $1.5 million in the prior year. Chief Executive Officer Eran Ophir said the company made important progress in 2025, citing the extension of its cash runway into 2029 through a non-dilutive monetization agreement with AstraZeneca for rilvegostomig. Ophir noted the agreement strengthens the company’s cash position while maintaining exposure to the potential long-term value of the asset, which AstraZeneca is advancing across 10 Phase 3 clinical trials in lung, gastrointestinal, and endometrial cancers, with additional Phase 1/2 data expected in 2026.

On February 12, 2026, Compugen Ltd. (NASDAQ:CGEN) announced the appointment of healthcare strategist Michele Holcomb as an independent director on its board. Holcomb brings more than 30 years of experience across biotechnology, pharmaceuticals, and healthcare services, including leadership roles at Cardinal Health, Teva, and McKinsey. The company said Holcomb’s background in strategy, business development, and partnerships is expected to support the use of its AI-driven discovery engine, pipeline development, and collaborations.

Compugen Ltd. (NASDAQ:CGEN) is a clinical-stage therapeutic discovery and development company focused on developing therapeutics and product candidates in Israel, the United States, and Europe.

While we acknowledge the potential of CGEN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CGEN and that has a 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 12 Best Tech Stocks that Beat Earnings Estimates and 40 Most Popular Stocks Among Hedge Funds Heading Into 2026

Disclosure: None. Follow Insider Monkey on Google News.